A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
Clinical trial NCT03557931 · COMPLETED
Trial details
- NCT number
- NCT03557931
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-13
- Primary completion
- 2019-10-21
- Enrollment
- 233
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.